PharmTech
CONTINUE TO SITE >

OR WAIT 15 SECS

Lonza to Expand its Small Molecule Services at Oregon Site

February 16, 2021
Pharmaceutical Technology Editors

The increased services will work in conjunction with the site’s SimpliFiH Solutions first-in-human services, which includes phase-appropriate drug substance and drug product development and manufacturing.

Lonza announced on Feb. 16, 2021 that it is expanding its solid form selection services at its Bend, OR site.

The increased services will work in conjunction with the site’s SimpliFiH Solutions first-in-human services, which includes phase-appropriate drug substance and drug product development and manufacturing, Lonza said in a company press release. The added services will also improve the company’s ability to meet accelerated timelines for complex molecules.

“We continue to expand and refine our first-in-human services based on what our customers are telling us,” said Christian Dowdeswell, vice-president and global head, Commercial Development – Small Molecules, Lonza, in the press release. “Choosing the right solid form and identifying the interplay between solid form and drug product is critical in the rapid advancement of molecules while minimizing risk and cost. Our expanded solid form services offering is designed to meet the early-stage molecule development of small biopharma players.”

“The overwhelming majority of new organic compounds have multiple forms and each drug and indication may require a tailored approach to lead form selection,” added Michael Grass, director of Solid Form Services – Small Molecules, Lonza, in the press release. “Our methodology, which builds on core competencies in material science and problem statement identification, is aimed at thorough solid form selection to ensure that all options for drug substances and drug product are considered early in the development process.”

Source: Lonza